37.13MMarket Cap2.20P/E (TTM)
4.1993High3.6604Low650.01KVolume3.9500Open3.8900Pre Close2.51MTurnover7.56%Turnover RatioLossP/E (Static)9.87MShares4.980052wk High2.67P/B32.33MFloat Cap1.050052wk Low--Dividend TTM8.60MShs Float30300.0000Historical High--Div YieldTTM13.85%Amplitude1.0214Historical Low3.8610Avg Price1Lot Size
iBio Inc Stock Forum
iBio to Begin Trading on the Nasdaq Stock Exchange
Wednesday, 19th February at 4:05 pm
SAN DIEGO, Feb. 19, 2025 (GLOBE NEWSWIRE) -- iBio, Inc.(NYSEA:IBIO), an AI-driven innovator of precision antibody therapies, today announced that iBio's common stock has been approved for listing on the Nasdaq Capital Market and iBio will transfer its stock exchange listing to Nasdaq Capital Market from the NYSE American. The Company expects to begin trading as a Nasdaq-listed company o...
📊⚡️📊
LFGGGG
1. NFA (Not Financial Advice!)
2. Do NOT open position WITHOUT chart confirmation, indicators, momentum.
3. Scale out and secure profits.
4. Most importantly, DON’T BLAME ME for your losses. Your trade, your accountability.
5. I DO NOT give buy or sell advice
6 COH (cash on hand); AH (after hours): RTH (regular trading hours); PR (press release; FCF (free cash flow)
7. NEVER be a blind follower.
LASTLY, If you d...
iBio Discovers Novel Antibody Targeting Activin E in Collaboration with AstralBio
Tuesday, 7th January at 7:00 am
SAN DIEGO, Jan. 07, 2025 (GLOBE NEWSWIRE) -- iBio, Inc.(NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, in collaboration with AstralBio Inc., announced today the development of an antibody that inhibits the function of Activin E, a promising therapeutic target for cardiometabolic disorders and obesity using iBio's patented Machine-L...
Benzinga· 3 mins ago
iBio, Inc. (NYSEA: IBIO), an AI-driven innovator of precision antibody immunotherapies, today announced the expansion of its cardiometabolic and obesity treatment development program by in-licensing a potentially best-in-class long-acting anti-myostatin antibody from AstralBio, Inc. The antibody, now named IBIO-600, was identified by AstralBio using iBio's proprieta...
No comment yet